NRx Pharmaceuticals Inc. and neurocare Group AG have entered a strategic partnership aimed at establishing a nationwide network of clinics focused on integrated neuroplastic care for mental health issues such as depression and post-traumatic stress disorder (PTSD). The collaboration seeks to address what both companies identify as a fragmented treatment landscape, bringing together neurocare’s neuromodulation technology and clinic infrastructure with NRx’s drug development initiatives under its HOPE Therapeutics brand.
This partnership capitalizes on the existing infrastructure of over 400 Apollo transcranial magnetic stimulation (TMS) machines already in operation throughout the United States. This setup allows the initiative to expand rapidly without the need for extensive new facilities. Early pilot programs, including a collaboration with a state first-responder agency, have demonstrated promising results by combining TMS with ketamine and other neuroplastic medications, along with hyperbaric oxygen therapy and structured psychotherapy.
Promising Results and Future Aspirations
The combined approach has yielded high remission rates among first responders dealing with PTSD and depression, who have traditionally been less responsive to conventional treatments. Recent peer-reviewed studies referenced by the companies indicate response rates as high as 87 percent and remission rates of 72 percent for patients with treatment-resistant depression when TMS is integrated with neuroplastic drug therapy. While both organizations acknowledge that this data is still preliminary and requires further validation, they assert that these outcomes warrant a broader clinical rollout and increased regulatory engagement.
Beyond depression and PTSD, NRx and neurocare are also looking into joint clinical trials targeting conditions like bipolar depression, autism spectrum disorder, and traumatic brain injury. This includes studies involving NRx’s investigational drug, NRX-101. The partnership reflects a commitment to industrializing mental health care in a manner similar to the standardization seen in other specialized medical fields.
Founded by former executives of Fresenius Medical Care, neurocare has dedicated over a decade to developing an integrated platform that includes neuromodulation technologies, clinician training programs, and proprietary software aimed at standardizing treatment intake, selection, and patient monitoring. NRx contributes its experience in neuroplastic drug development and clinic-based care, currently servicing government programs such as the VA Community Care Network and the Department of Defense’s TRICARE system.
Aiming for Accessible, Integrated Care
The alliance will initially utilize neurocare and HOPE Therapeutics clinics, which currently number around 20 in the United States, while also welcoming independent providers operating Apollo TMS systems. The objective is to ensure that integrated neuroplastic treatment becomes accessible to most U.S. households by the end of 2026.
Leaders at both companies describe this initiative as a pivotal moment for both clinical and commercial advancement. Serious central nervous system disorders affect over 50 million individuals in the United States and approximately 500 million globally, highlighting a significant unmet need in healthcare. By creating a single point of accountable care, NRx and neurocare aim to minimize treatment fragmentation and establish a scalable business model in an industry increasingly scrutinized for outcomes and cost efficiency.
Executives from both organizations are set to present their strategy to investors and industry stakeholders at the upcoming JP Morgan Healthcare Conference in San Francisco, underscoring their ambition to develop this partnership into a national platform rather than a limited clinical collaboration.
